NCT05968885View on ClinicalTrials.gov

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity

PHASE4RecruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Urinary Bladder, OveractiveUrodynamicsEffect of Drug

Interventions

PROCEDURE

Intradetrusor Botox® (onabotulinumtoxinA) injection

The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.

DRUG

Combine Mirabegron and Solifenacin.

Combination pharmacotherapy

Trial Locations (1)

Unknown

RECRUITING

Mackay Memorial Hospital, Taipei

All Listed Sponsors

lead

Mackay Memorial Hospital

OTHER